I. Jeziskova

发表

Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, Molecular Diagnosis & Therapy.

Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML

D. Dvořáková, J. Mayer, Z. Ráčil, 2015, International Journal of Hematology.

Cytochrome P450 2D6 phenotype and genotype in hypertensive patients on long-term therapy with metoprolol.

M. Grundmann, J. Duricova, I. Kacířová, 2013, Bratislavske lekarske listy.

Donor-derived DNA variability in fingernails of acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation detected by direct PCR

J. Mayer, A. Folta, M. Krejci, 2020, Bone Marrow Transplantation.

Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene

D. Dvořáková, J. Mayer, Z. Ráčil, 2013, Leukemia & lymphoma.

Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients

J. Mayer, A. Folta, D. Zackova, 2020, Leukemia & lymphoma.

Analysis of Mutations in the BCR-ABL1 Kinase Domain, Using Direct Sequencing

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, Molecular Diagnosis & Therapy.

Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, Molecular diagnosis & therapy.

A Case of a Novel PML/RARA Short Fusion Transcript with Truncated Transcription Variant 2 of the RARA Gene

D. Dvořáková, M. Doubek, J. Mayer, 2010, Molecular Diagnosis & Therapy.

Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse

J. Kissová, D. Dvořáková, J. Mayer, 2011, International journal of laboratory hematology.

CEBPA Gene Mutational Status

D. Dvořáková, J. Mayer, F. Rázga, 2012, Molecular Diagnosis & Therapy.

CEBPA Gene Mutational Status

D. Dvořáková, J. Mayer, F. Rázga, 2012, Molecular Diagnosis & Therapy.

Germline variants of the promyelocytic leukemia tumor suppressor gene in patients with familial cancer.

L. Forétova, J. Zapletalová, A. Křepelová, 2009, Neoplasma.

Novel complex mutation in NPM1 gene in patient with acute myeloid leukemia

D. Dvořáková, J. Mayer, Z. Ráčil, 2017, Leukemia & lymphoma.

Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations

D. Dvořáková, J. Mayer, Z. Ráčil, 2013, Leukemia & lymphoma.

Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients

P. Žák, F. Pardy, Z. Ráčil, 2022, Leukemia & lymphoma.

Effective NPM1 plasmid standards selection for minimal/measurable residual disease monitoring in acute myeloid leukemia

A. Folta, Markéta Šašinková, I. Jeziskova, 2022, Molecular Biology Reports.

Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, American journal of hematology.

Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient‐specific NPM1 mutations

D. Dvořáková, J. Mayer, Z. Ráčil, 2010, American journal of hematology.

The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice

J. Chovancová, V. Bystrý, D. Dvořáková, 2018, Journal of Cancer Research and Clinical Oncology.

Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients

D. Dvořáková, P. Žák, J. Mayer, 2019, British journal of haematology.

Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.

Martin Klabusay, Michael Doubek, D. Dvořáková, 2009, Experimental hematology.

IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status

D. Dvořáková, J. Mayer, Z. Ráčil, 2010, Leukemia & lymphoma.

Clonal hierarchy of main molecular lesions in acute myeloid leukaemia

J. Mayer, Z. Ráčil, A. Folta, 2019, British journal of haematology.

Failure of molecular diagnostics in chronic myeloid leukemia: an aberrant form of e13a2 BCR–ABL transcript causing false-negative results by standard polymerase chain reaction

J. Mayer, F. Rázga, D. Zackova, 2010, Leukemia & lymphoma.

A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel

D. Kundrát, Z. Ráčil, A. Folta, 2022, Clinical epigenetics.

Limited efficacy of HLA‐haploidentical peripheral blood stem cell infusion in treatment of elderly patients with acute myelogenous leukaemia

J. Mayer, Z. Ráčil, O. Horký, 2017, Hematological oncology.

Genesis of new allele at locus D2S1360 in leukemia patient

J. Mayer, M. Krejci, I. Jeziskova, 2017, Leukemia & lymphoma.

The use of RAPD and AFLP markers for Characterisation of Winter Barley Genotypes for Breeding to Fusarium Head Blight Resistance

M. Pouch, Z. Nesvadba, I. Jeziskova, 2008 .

Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient‐specific NPM1 mutations

J. Mayer, Z. Ráčil, M. Lengerova, 2010, American journal of hematology.

Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene

J. Mayer, Z. Ráčil, F. Rázga, 2013, Leukemia & lymphoma.

MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemia

D. Kundrát, A. Folta, P. Cetkovský, 2024, Clinical epigenetics.

Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF

P. Jindra, A. Folta, T. Papajík, 2024, Leukemia.

Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse

F. Rázga, O. Horký, L. Kablásková, 2011, International journal of laboratory hematology.